{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:25:34Z","timestamp":1789133134787,"version":"build-2803163510"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Isavuconazole is first-line treatment of invasive aspergillosis. Therapeutic drug monitoring (TDM) is deemed not necessary, since most patients reached therapeutic levels (&amp;gt;1\u2005mg\/L) in large studies. Low levels were reported in some critically ill patients admitted to the ICU. The aim was to compare isavuconazole levels between critically ill and non-critically ill patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and methods<\/jats:title>\n                  <jats:p>Retrospective analysis of data from all patients treated with standard-dose isavuconazole between 1 January 2019 and 26 October 2022 was performed. The following data were collected: TDM results from the first 30\u2005days of therapy; ward of admission; demographic and clinical characteristics; continuous renal replacement therapy; extracorporeal membrane oxygenation; and co-administered drugs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventy-two patients (median age 65\u2005years) and 188 TDM measurements (mean number of samples per patient 2.6\u200a\u00b1\u200a1.7) were included; 33 (45.8%) were ICU patients (3 also had haematological disorders); 39 (54.2%) were non-ICU patients, of whom 31 had haematological disorders. In all patients, the mean isavuconazole blood level was 3.33\u200a\u00b1\u200a2.26\u2005mg\/L. Significantly lower levels were observed in the ICU versus the non-ICU population: mean 2.02\u200a\u00b1\u200a1.22 versus 4.15\u200a\u00b1\u200a2.31\u2005mg\/L (P\u200a&amp;lt;\u200a0.001). Significantly higher rates of subtherapeutic levels were observed in ICU patients compared with the non-ICU population: all determinations &amp;lt;2\u2005mg\/L in 33.3% versus 7.7%, and all determinations &amp;lt;1\u2005mg\/L in 12.1% versus 0%, respectively. Predictors of lower isavuconazole levels were admission to the ICU, BMI\u200a&amp;gt;\u200a25\u2005kg\/m2, bilirubin\u200a&amp;gt;\u200a1.2\u2005mg\/dL and the absence of haematological disorder.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>ICU patients had significantly lower isavuconazole blood levels compared to non-ICU population. The TDM of isavuconazole for efficacy should be performed in ICU.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae037","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T05:38:20Z","timestamp":1708148300000},"page":"835-845","source":"Crossref","is-referenced-by-count":26,"title":["Lower blood levels of isavuconazole in critically ill patients compared with other populations: possible need for therapeutic drug monitoring"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5535-4602","authenticated-orcid":false,"given":"Malgorzata","family":"Mikulska","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Health Sciences, University of Genova , Genova , Italy"},{"name":"Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Melchio","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Health Sciences, University of Genova , Genova , Italy"},{"name":"Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Signori","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Biostatistics, University of Genoa , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadir","family":"Ullah","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Health Sciences, University of Genova , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca","family":"Miletich","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Health Sciences, University of Genova , Genova , Italy"},{"name":"Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1761-436X","authenticated-orcid":false,"given":"Chiara","family":"Sepulcri","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Health Sciences, University of Genova , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Limongelli","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Health Sciences, University of Genova , Genova , Italy"},{"name":"Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2385-1759","authenticated-orcid":false,"given":"Daniele Roberto","family":"Giacobbe","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Health Sciences, University of Genova , Genova , Italy"},{"name":"Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Balletto","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Russo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Health Sciences, University of Genova , Genova , Italy"},{"name":"Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Magnasco","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vena","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Health Sciences, University of Genova , Genova , Italy"},{"name":"Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Di Grazia","sequence":"additional","affiliation":[{"name":"Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Raiola","sequence":"additional","affiliation":[{"name":"Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Portunato","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9096-5812","authenticated-orcid":false,"given":"Chiara","family":"Dentone","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Battaglini","sequence":"additional","affiliation":[{"name":"Anesthesia and Intensive Care, IRCCS Ospedale Policlinico San Martino , Genova , Italy"},{"name":"Department of Surgical Sciences and Integrated Diagnostics, University of Genoa , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Ball","sequence":"additional","affiliation":[{"name":"Anesthesia and Intensive Care, IRCCS Ospedale Policlinico San Martino , Genova , Italy"},{"name":"Department of Surgical Sciences and Integrated Diagnostics, University of Genoa , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1628-3845","authenticated-orcid":false,"given":"Chiara","family":"Robba","sequence":"additional","affiliation":[{"name":"Anesthesia and Intensive Care, IRCCS Ospedale Policlinico San Martino , Genova , Italy"},{"name":"Department of Surgical Sciences and Integrated Diagnostics, University of Genoa , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Angelucci","sequence":"additional","affiliation":[{"name":"Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iole","family":"Brunetti","sequence":"additional","affiliation":[{"name":"Anesthesia and Intensive Care, IRCCS Ospedale Policlinico San Martino , Genova , Italy"},{"name":"Department of Surgical Sciences and Integrated Diagnostics, University of Genoa , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Health Sciences, University of Genova , Genova , Italy"},{"name":"Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"2024040202342533100_dkae037-B1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jinf.2018.02.012","article-title":"The burden of invasive aspergillosis in patients with haematological malignancy: a meta-analysis and systematic review","volume":"76","author":"van de Peppel","year":"2018","journal-title":"J Infect"},{"key":"2024040202342533100_dkae037-B2","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024040202342533100_dkae037-B3","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024040202342533100_dkae037-B4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.201111-1978OC","article-title":"A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients","volume":"186","author":"Blot","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2024040202342533100_dkae037-B5","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/jof7121067","article-title":"A visual and comprehensive review on COVID-19-associated pulmonary aspergillosis (CAPA)","volume":"7","author":"Feys","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2024040202342533100_dkae037-B6","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.cmi.2022.01.027","article-title":"Defining COVID-19-associated pulmonary aspergillosis: systematic review and meta-analysis","volume":"28","author":"Kariyawasam","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2024040202342533100_dkae037-B7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s15010-021-01701-x","article-title":"Comparing the clinical characteristics and outcomes of COVID-19-associate pulmonary aspergillosis (CAPA): a systematic review and meta-analysis","volume":"50","author":"Chong","year":"2022","journal-title":"Infection"},{"key":"2024040202342533100_dkae037-B8","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2024040202342533100_dkae037-B9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2024040202342533100_dkae037-B10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2024040202342533100_dkae037-B11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/dky463","article-title":"Variability and exposure\u2013response relationships of isavuconazole plasma concentrations in the phase 3 SECURE trial of patients with invasive mould diseases","volume":"74","author":"Kaindl","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024040202342533100_dkae037-B12","doi-asserted-by":"crossref","first-page":"e01034-17","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024040202342533100_dkae037-B13","doi-asserted-by":"crossref","first-page":"e00585-18","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024040202342533100_dkae037-B14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/jof6020090","article-title":"Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: outcome, tolerability and clinical implications of isavuconazole plasma concentrations","volume":"6","author":"Zurl","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2024040202342533100_dkae037-B15","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/myc.13469","article-title":"Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis","volume":"65","author":"H\u00f6hl","year":"2022","journal-title":"Mycoses"},{"key":"2024040202342533100_dkae037-B16","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1093\/jac\/dkac196","article-title":"Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation","volume":"77","author":"Kriegl","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2024040202342533100_dkae037-B17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13054-022-04093-y","article-title":"The impact of extracorporeal membrane oxygenation on the exposure to isavuconazole: a plea for thorough pharmacokinetic evaluation","volume":"26","author":"Mertens","year":"2022","journal-title":"Crit Care"},{"key":"2024040202342533100_dkae037-B18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/jof9020211","article-title":"Population pharmacokinetics of isavuconazole in critical care patients with COVID-19-associated pulmonary aspergillosis and Monte Carlo simulations of high off-label doses","volume":"9","author":"Perez","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"2024040202342533100_dkae037-B19","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024040202342533100_dkae037-B20","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024040202342533100_dkae037-B21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2016","journal-title":"Eur Respir J"},{"key":"2024040202342533100_dkae037-B22","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024040202342533100_dkae037-B23","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1093\/cid\/ciaa1751","article-title":"EORTC\/MSGERC definitions of invasive fungal diseases: summary of activities of the intensive care unit working group","volume":"72","author":"Bassetti","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024040202342533100_dkae037-B24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/fcp.12507","article-title":"Refining the therapeutic range of posaconazole and isavuconazole for efficient therapeutic drug monitoring using a bioassay approach","volume":"34","author":"Willeman","year":"2020","journal-title":"Fundam Clin Pharmacol"},{"key":"2024040202342533100_dkae037-B25","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1128\/AAC.02665-15","article-title":"Pharmacokinetics and concentration-dependent efficacy of isavuconazole for treatment of experimental invasive pulmonary aspergillosis","volume":"60","author":"Petraitis","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024040202342533100_dkae037-B26","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.cmi.2020.06.007","article-title":"How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European Committee on Antimicrobial Susceptibility Testing (EUCAST)","volume":"26","author":"Arendrup","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2024040202342533100_dkae037-B27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/antibiotics10050487","article-title":"Therapeutic drug monitoring of isavuconazole: serum concentration variability and success rates for reaching target in comparison with voriconazole","volume":"10","author":"Risum","year":"2021","journal-title":"Antibiotics"},{"key":"2024040202342533100_dkae037-B28","doi-asserted-by":"crossref","first-page":"5756","DOI":"10.3390\/jcm11195756","article-title":"Variability of isavuconazole trough concentrations during longitudinal therapeutic drug monitoring","volume":"11","author":"Bolcato","year":"2022","journal-title":"J Clin Med"},{"key":"2024040202342533100_dkae037-B29","doi-asserted-by":"crossref","first-page":"e01643-18","DOI":"10.1128\/AAC.01643-18","article-title":"Pharmacokinetics of intravenous isavuconazole in solid-organ transplant recipients","volume":"62","author":"Wu","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024040202342533100_dkae037-B30","doi-asserted-by":"crossref","first-page":"e01085-19","DOI":"10.1128\/AAC.01085-19","article-title":"Pharmacokinetics and dialytic clearance of isavuconazole during in vitro and in vivo continuous renal replacement therapy","volume":"63","author":"Biagi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024040202342533100_dkae037-B31","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1128\/AAC.02942-15","article-title":"Population pharmacokinetics of isavuconazole in subjects with mild or moderate hepatic impairment","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024040202342533100_dkae037-B32","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.3390\/pharmaceutics13122099","article-title":"Population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against Aspergillus fumigatus and Aspergillus flavus in adult patients with invasive fungal diseases: should therapeutic drug monitoring for isavuconazole be considered as mandatory as for the other mold-active azoles?","volume":"13","author":"Cojutti","year":"2021","journal-title":"Pharmaceutics"},{"key":"2024040202342533100_dkae037-B33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cpdd.284","article-title":"Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults","volume":"6","author":"Groll","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2024040202342533100_dkae037-B34","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1177\/10781552211029046","article-title":"Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations","volume":"28","author":"Gu","year":"2022","journal-title":"J Oncol Pharm Pract"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/4\/835\/57130669\/dkae037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/4\/835\/57130669\/dkae037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T02:35:12Z","timestamp":1712025312000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/4\/835\/7608753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2,15]]},"published-print":{"date-parts":[[2024,4,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae037","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,2,15]]}}}